Bristol Myers buys Orbital Therapeutics for $1.5 billion
Drugmaker Bristol Myers Squibb said today it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing competition from generic drugs.
Business
• 10 Oct
